ArticleMedicine2025
Evaluating the causal role of circulating inflammatory cytokines and plasma metabolites on aplastic anemia.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aplastic anemia (AA) is a rare, potentially life-threatening bone marrow failure syndrome characterized by immune-mediated destruction of hematopoietic stem/progenitor cells. Inflammatory cytokines and plasma metabolites are key regulators of T cell activity, but their causal roles in AA pathogenesis remain to be clarified. Two-sample Mendelian randomization (MR) was used to assess causal relationships between 91 circulating inflammatory cytokines, 1400 blood metabolites, and AA risk, and further mediation Mendelian randomization was applied to explore potential mediating pathways, with inverse-variance weighted method as the primary statistical method. Interleukin-13 (IL-13) is causally associated with reduced AA risk (odds ratio = 0.8731, 95% CI = 0.7720-0.9876, P = .0308), while leukemia inhibitory factor receptor (LIFR) links to increased risk (odds ratio = 1.1677, 95% CI = 1.0463-1.3031, P = .0056). Forty six plasma metabolites showed casual associated with AA, among which perfluorooctane sulfonate, andro steroid monosulfate, hydroxy-cmpf, spermidine to N-acetylputrescine ratio, cysteine to 5-oxoproline ratio, pyruvate to 3-methyl-2-oxobutyrate ratio, X-25520, epiandrosterone sulfate, epiandrosterone sulfate, N-acetyl-beta-alanine, cholate to adenosine 5'-monophosphate (AMP), spermidine to histidine ratio, cysteine s-sulfate have the most significant effects (P < .01). No causal effect of AA on IL-13 or LIFR, though AA may lower levels of 4 metabolites. IL-13 and LIFR affect the blood concentrations of 6 metabolites, and 3 metabolites influence IL-13 or LIFR levels, no evidence supports these metabolites acting as intermediaries in regulating AA risk. This study identifies inflammatory cytokines and blood metabolites as potential pathogenic factors in AA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.